Literature DB >> 6281153

Specific binding sites on human blood platelets for plasma lipoproteins.

E Koller, F Koller, W Doleschel.   

Abstract

Scatchard analysis of the binding of homologous plasma low density lipoproteins (LDL) to human blood platelets shows the existence of a uniform class of saturable specific binding sites. Platelets from healthy donors bound 1470 +/- 640 molecules of LDL per platelet, the constant of association Ka = (6.2 +/- 2.2) X 10-7 l x mol-1. Binding kinetics, temperature dependence, and experiments with formaldehyde-fixed platelets showed that internalization of LDL (at least the labelled apoprotein moiety) did not occur to any considerable degree under the experimental conditions employed. Both very low density lipoproteins (VLDL) and high density lipoproteins 3 (HDL3) markedly inhibited the binding of LDL. In contrast to LDL, HDL3 bound to 3200 +/- 410 binding sites per platelet with a Ka = (9 +/- 1.7) X 10(7) l x mol-1. Additionally, the results of inhibition experiments using both LDL and HDL3 in combination gave evidence, that the sites for HDL3 binding were not identical with those for LDL binding and each inhibited binding of the other noncompetitively with reduction of the binding affinity and the number of available binding sites. VLDL bound to the platelet plasma membrane in a nonspecific-nonsaturable way. Possible significances of the presence of specific LDL receptors on the platelet plasma membrane for recognized functions of these blood elements are discussed.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6281153     DOI: 10.1515/bchm2.1982.363.1.395

Source DB:  PubMed          Journal:  Hoppe Seylers Z Physiol Chem        ISSN: 0018-4888


  11 in total

Review 1.  The blood compatibility challenge. Part 2: Protein adsorption phenomena governing blood reactivity.

Authors:  John L Brash; Thomas A Horbett; Robert A Latour; Pentti Tengvall
Journal:  Acta Biomater       Date:  2019-06-18       Impact factor: 8.947

2.  Intracellular mechanisms in the activation of human platelets by low-density lipoproteins.

Authors:  H E Andrews; J W Aitken; D G Hassall; V O Skinner; K R Bruckdorfer
Journal:  Biochem J       Date:  1987-03-01       Impact factor: 3.857

3.  Role of platelets in cholesteryl ester formation by U-937 cells.

Authors:  M E Mendelsohn; J Loscalzo
Journal:  J Clin Invest       Date:  1988-01       Impact factor: 14.808

Review 4.  Platelet activation in normo- and hyperlipoproteinemias.

Authors:  J Nimpf; H Wurm; G M Kostner; T Kenner
Journal:  Basic Res Cardiol       Date:  1986 Sep-Oct       Impact factor: 17.165

Review 5.  Scavenger receptor BI: a multi-purpose player in cholesterol and steroid metabolism.

Authors:  Menno Hoekstra; Theo-Jc Van Berkel; Miranda Van Eck
Journal:  World J Gastroenterol       Date:  2010-12-21       Impact factor: 5.742

6.  Transfer of phosphatidylcholine, phosphatidylethanolamine and sphingomyelin from low- and high-density lipoprotein to human platelets.

Authors:  B Engelmann; C Kögl; R Kulschar; B Schaipp
Journal:  Biochem J       Date:  1996-05-01       Impact factor: 3.857

7.  The effects of bicarbonate and acetate haemodialysis on platelet cyclic AMP concentration, thromboxane B2 release and aggregation.

Authors:  S Túri; C Bereczki; C Torday; Z Havass; M Németh
Journal:  Pediatr Nephrol       Date:  1991-05       Impact factor: 3.714

8.  The effect of low-density lipoproteins on the synthesis of cyclic nucleotides induced by prostacyclin in isolated platelets.

Authors:  K R Bruckdorfer; S Buckley; D G Hassall
Journal:  Biochem J       Date:  1984-10-01       Impact factor: 3.857

9.  The aggregation of isolated human platelets in the presence of lipoproteins and prostacyclin.

Authors:  D G Hassall; J S Owen; K R Bruckdorfer
Journal:  Biochem J       Date:  1983-10-15       Impact factor: 3.857

10.  Native and modified low-density-lipoprotein interaction with human platelets in normal and homozygous familial-hypercholesterolaemic subjects.

Authors:  A Shmulewitz; J G Brook; M Aviram
Journal:  Biochem J       Date:  1984-11-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.